Arvinas/$ARVN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arvinas
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
- Ticker
- $ARVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 246
- Headquarters
- New Haven, United States
- Website
- www.arvinas.com
Arvinas Metrics
BasicAdvanced
$456M
52.14
$0.13
1.76
-
Price and volume
Market cap
$456M
Beta
1.76
52-week high
$14.51
52-week low
$6.74
Average daily volume
831K
Financial strength
Current ratio
7.905
Quick ratio
7.542
Long term debt to equity
0.011
Total debt to equity
0.014
Profitability
EBITDA (TTM)
-9.9
Gross margin (TTM)
97.16%
Net profit margin (TTM)
2.94%
Operating margin (TTM)
-4.04%
Effective tax rate (TTM)
7.92%
Revenue per employee (TTM)
$1,290,000
Management effectiveness
Return on assets (TTM)
-1.01%
Return on equity (TTM)
1.59%
Valuation
Price to earnings (TTM)
52.139
Price to revenue (TTM)
1.468
Price to book
0.81
Price to tangible book (TTM)
0.81
Price to free cash flow (TTM)
-2.227
Free cash flow yield (TTM)
-44.91%
Free cash flow per share (TTM)
-3.13
Growth
Revenue change (TTM)
-15.05%
Earnings per share change (TTM)
-113.34%
3-year revenue growth (CAGR)
26.06%
3-year earnings per share growth (CAGR)
-71.17%
What the Analysts think about Arvinas
Analyst ratings (Buy, Hold, Sell) for Arvinas stock.
Analyst projections of the future price of Arvinas stock.
Bulls say / Bears say
VEPPANU’s FDA approval is the first for a PROTAC, giving Arvinas’ protein-degradation approach a real regulatory and clinical validation in advanced breast cancer. (Reuters)
The Rigel licence creates a route to value from VEPPANU without Arvinas having to lead its global commercialisation: Arvinas and Pfizer are eligible for an aggregate $70 million upfront, further milestones and royalties. (Arvinas)
The strong second-quarter revenue and profit are not a dependable run rate: results included recognition of deferred Pfizer revenue, a Rigel licence payment and a $50 million approval milestone. Arvinas said no revenue recognition would remain under the original Pfizer collaboration after that quarter. (Arvinas)
VEPPANU’s commercial upside now depends on Rigel’s launch and sales execution, while Arvinas has licensed away the global development and commercialisation rights. Weak uptake would limit the value of the asset to Arvinas and Pfizer’s milestone and royalty returns. (Arvinas)
Important pipeline evidence remains uncertain or delayed: Arvinas expects to start ARV-102 trials in progressive supranuclear palsy in 2027 after regulatory requests, and most of the planned 2026 ARV-393 data will come from dose cohorts below the company’s predicted efficacious range. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Arvinas Financial Performance
Revenues and expenses
Arvinas Earnings Performance
Company profitability
Upcoming events
No upcoming events
Arvinas News
AllArticlesVideos
Funds containing Arvinas
AllUSDEURGBP
Fund name | Fund size | $ARVN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.05% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.05% |
iShares Healthcare Innovation£DRDR | £1B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.